Want to join the conversation?
Globally, $AMGN's product sales grew 6% in 3Q15 and US business grew 20%. International business grew 3% YoverY, excluding the negative impact of FX. Repatha is expected to be approved in Japan in 1H16. Kyprolis, which grew 46% in 3Q15, is expected to be approved in Europe, Canada and parts of South America and Asia by year-end.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.